Cannabinoids reduce ErbB2-driven breast cancer progression through Akt inhibition

Molecular Cancer

Volumn 9, Issue , 2010, Pages

  Caffarel, María M ^a,e,f   Andradas, Clara ^a   Mira, Emilia ^b   Pérez Gómez, Eduardo ^a   Cerutti, Camilla ^a,e   Moreno Bueno, Gema ^c   Flores, Juana M ^a   García Real, Isabel ^a   Palacios, José ^d   Mañes, Santos ^b   Guzmán, Manuel ^a   Sánchez, Cristina ^a  

^a UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

^b CENTRO NACIONAL DE BIOTECNOLOGÍA   (Spain)

^c INSTITUTO DE INVESTIGACIONES BIOMÉDICAS ALBERTO SOLS   (Spain)

^d HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

^e UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^f OPEN UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

1 DEOXY 3 (1,1 DIMETHYLBUTYL) DELTA8 TETRAHYDROCANNABINOL; 5 (4 CHLORO 3 METHYLPHENYL) 1 (4 METHYLBENZYL) N (1,3,3 TRIMETHYLBICYCLO[2.2.1]HEPTAN 2 YL) 3 PYRAZOLECARBOXAMIDE; CANNABINOID 2 RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; GELATINASE A; GELATINASE B; MESSENGER RNA; PROTEIN KINASE B; TETRAHYDROCANNABINOLIC ACID; CANNABINOID; PROTEIN KINASE INHIBITOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BREAST CANCER; BREAST CARCINOGENESIS; CANCER INHIBITION; CANCER INVASION; CANCER MORPHOLOGY; CANCER REGRESSION; CELL PROLIFERATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; ENZYME ACTIVITY; ENZYME INHIBITION; FEMALE; GENE OVEREXPRESSION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; IN VIVO STUDY; LUNG METASTASIS; MOUSE; NONHUMAN; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TUMOR VASCULARIZATION; BREAST TUMOR; DISEASE COURSE; DRUG ANTAGONISM; METABOLISM; METASTASIS; PATHOLOGY; PHYSIOLOGY;

CANNABIS SATIVA; MOUSE MAMMARY TUMOR VIRUS; MUS;

BREAST NEOPLASMS; CANNABINOIDS; DISEASE PROGRESSION; DOWN-REGULATION; FEMALE; HUMANS; NEOPLASM METASTASIS; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-AKT; RECEPTOR, CANNABINOID, CB2; RECEPTOR, ERBB-2;

EID: 77954789824     PISSN: None     EISSN: 14764598     Source Type: Journal    
DOI: 10.1186/1476-4598-9-196     Document Type: Article

References (36)

1. Baselga J, Swain SM. Novel anticancer targets: revisiting ERBB2 and discovering ERBB3. Nat Rev Cancer 2009, 9:463-475. 10.1038/nrc2656, 19536107.
2. Ursini-Siegel J, Schade B, Cardiff RD, Muller WJ. Insights from transgenic mouse models of ERBB2-induced breast cancer. Nat Rev Cancer 2007, 7:389-397. 10.1038/nrc2127, 17446858.
3. Di Cosimo S, Baselga J. Targeted therapies in breast cancer: where are we now?. Eur J Cancer 2008, 44:2781-2790. 10.1016/j.ejca.2008.09.026, 19013786.
4. Hynes NE, Lane HA. ERBB receptors and cancer: the complexity of targeted inhibitors. Nat Rev Cancer 2005, 5:341-354. 10.1038/nrc1609, 15864276.
5. Di Marzo V. Targeting the endocannabinoid system: to enhance or reduce?. Nat Rev Drug Discov 2008, 7:438-455. 10.1038/nrd2553, 18446159.
6. Pertwee RG. Emerging strategies for exploiting cannabinoid receptor agonists as medicines. Br J Pharmacol 2009, 156:397-411. 10.1111/j.1476-5381.2008.00048.x, 2697681, 19226257.
7. Guzman M. Cannabinoids: potential anticancer agents. Nat Rev Cancer 2003, 3:745-755. 10.1038/nrc1188, 14570037.
8. Sarfaraz S, Adhami VM, Syed DN, Afaq F, Mukhtar H. Cannabinoids for cancer treatment: progress and promise. Cancer Res 2008, 68:339-342. 10.1158/0008-5472.CAN-07-2785, 18199524.
9. Guy CT, Webster MA, Schaller M, Parsons TJ, Cardiff RD, Muller WJ. Expression of the neu protooncogene in the mammary epithelium of transgenic mice induces metastatic disease. Proc Natl Acad Sci USA 1992, 89:10578-10582. 10.1073/pnas.89.22.10578, 50384, 1359541.
10. Chambers AF, Groom AC, MacDonald IC. Dissemination and growth of cancer cells in metastatic sites. Nat Rev Cancer 2002, 2:563-572. 10.1038/nrc865, 12154349.
11. Moasser MM. The oncogene HER2: its signaling and transforming functions and its role in human cancer pathogenesis. Oncogene 2007, 26:6469-6487. 10.1038/sj.onc.1210477, 17471238.
12. Manning BD, Cantley LC. AKT/PKB signaling: navigating downstream. Cell 2007, 129:1261-1274. 10.1016/j.cell.2007.06.009, 2756685, 17604717.
13. Nanni P, Pupa SM, Nicoletti G, De Giovanni C, Landuzzi L, Rossi I, Astolfi A, Ricci C, De Vecchi R, Invernizzi AM, et al. p185(neu) protein is required for tumor and anchorage-independent growth, not for cell proliferation of transgenic mammary carcinoma. Int J Cancer 2000, 87:186-194. 10.1002/1097-0215(20000715)87:2<186::AID-IJC5>3.0.CO;2-1, 10861472.
14. Dean-Colomb W, Esteva FJ. Her2-positive breast cancer: herceptin and beyond. Eur J Cancer 2008, 44:2806-2812. 10.1016/j.ejca.2008.09.013, 19022660.
15. Hutchinson JN, Jin J, Cardiff RD, Woodgett JR, Muller WJ. Activation of Akt-1 (PKB-alpha) can accelerate ErbB-2-mediated mammary tumorigenesis but suppresses tumor invasion. Cancer Res 2004, 64:3171-3178. 10.1158/0008-5472.CAN-03-3465, 15126356.
16. Caffarel MM, Moreno-Bueno G, Cerutti C, Palacios J, Guzman M, Mechta-Grigoriou F, Sanchez C. JunD is involved in the antiproliferative effect of Delta(9)-tetrahydrocannabinol on human breast cancer cells. Oncogene 2008, 27:5033-5044. 10.1038/onc.2008.145, 18454173.
17. Caffarel MM, Sarrio D, Palacios J, Guzman M, Sanchez C. Delta9-tetrahydrocannabinol inhibits cell cycle progression in human breast cancer cells through Cdc2 regulation. Cancer Res 2006, 66:6615-6621. 10.1158/0008-5472.CAN-05-4566, 16818634.
18. De Petrocellis L, Melck D, Palmisano A, Bisogno T, Laezza C, Bifulco M, Di Marzo V. The endogenous cannabinoid anandamide inhibits human breast cancer cell proliferation. Proc Natl Acad Sci USA 1998, 95:8375-8380. 10.1073/pnas.95.14.8375, 20983, 9653194.
19. Laezza C, Pisanti S, Crescenzi E, Bifulco M. Anandamide inhibits Cdk2 and activates Chk1 leading to cell cycle arrest in human breast cancer cells. FEBS Lett 2006, 580:6076-6082. 10.1016/j.febslet.2006.09.074, 17055492.
20. Ligresti A, Moriello AS, Starowicz K, Matias I, Pisanti S, De Petrocellis L, Laezza C, Portella G, Bifulco M, Di Marzo V. Antitumor activity of plant cannabinoids with emphasis on the effect of cannabidiol on human breast carcinoma. J Pharmacol Exp Ther 2006, 318:1375-1387. 10.1124/jpet.106.105247, 16728591.
21. Qamri Z, Preet A, Nasser MW, Bass CE, Leone G, Barsky SH, Ganju RK. Synthetic cannabinoid receptor agonists inhibit tumor growth and metastasis of breast cancer. Mol Cancer Ther 2009, 8:3117-3129. 10.1158/1535-7163.MCT-09-0448, 19887554.
22. Melck D, De Petrocellis L, Orlando P, Bisogno T, Laezza C, Bifulco M, Di Marzo V. Suppression of nerve growth factor Trk receptors and prolactin receptors by endocannabinoids leads to inhibition of human breast and prostate cancer cell proliferation. Endocrinology 2000, 141:118-126. 10.1210/en.141.1.118, 10614630.
23. Melck D, Rueda D, Galve-Roperh I, De Petrocellis L, Guzman M, Di Marzo V. Involvement of the cAMP/protein kinase A pathway and of mitogen-activated protein kinase in the anti-proliferative effects of anandamide in human breast cancer cells. FEBS Lett 1999, 463:235-240. 10.1016/S0014-5793(99)01639-7, 10606728.
24. Frese KK, Tuveson DA. Maximizing mouse cancer models. Nat Rev Cancer 2007, 7:645-658. 10.1038/nrc2192, 17687385.
25. Wang D, Wang H, Ning W, Backlund MG, Dey SK, DuBois RN. Loss of cannabinoid receptor 1 accelerates intestinal tumor growth. Cancer Res 2008, 68:6468-6476. 10.1158/0008-5472.CAN-08-0896, 2561258, 18676872.
26. Izzo AA, Aviello G, Petrosino S, Orlando P, Marsicano G, Lutz B, Borrelli F, Capasso R, Nigam S, Capasso F, Di Marzo V. Increased endocannabinoid levels reduce the development of precancerous lesions in the mouse colon. J Mol Med 2008, 86:89-98. 10.1007/s00109-007-0248-4, 2755791, 17823781.
27. Lopez-Otin C, Matrisian LM. Emerging roles of proteases in tumour suppression. Nat Rev Cancer 2007, 7:800-808. 10.1038/nrc2228, 17851543.
28. Mira E, Lacalle RA, Buesa JM, de Buitrago GG, Jimenez-Baranda S, Gomez-Mouton C, Martinez AC, Manes S. Secreted MMP9 promotes angiogenesis more efficiently than constitutive active MMP9 bound to the tumor cell surface. J Cell Sci 2004, 117:1847-1857. 10.1242/jcs.01035, 15075244.
29. Scorilas A, Karameris A, Arnogiannaki N, Ardavanis A, Bassilopoulos P, Trangas T, Talieri M. Overexpression of matrix-metalloproteinase-9 in human breast cancer: a potential favourable indicator in node-negative patients. Br J Cancer 2001, 84:1488-1496. 10.1054/bjoc.2001.1810, 2363667, 11384099.
30. Pisanti S, Borselli C, Oliviero O, Laezza C, Gazzerro P, Bifulco M. Antiangiogenic activity of the endocannabinoid anandamide: correlation to its tumor-suppressor efficacy. J Cell Physiol 2007, 211:495-503. 10.1002/jcp.20954, 17192847.
31. Blazquez C, Salazar M, Carracedo A, Lorente M, Egia A, Gonzalez-Feria L, Haro A, Velasco G, Guzman M. Cannabinoids inhibit glioma cell invasion by down-regulating matrix metalloproteinase-2 expression. Cancer Res 2008, 68:1945-1952. 10.1158/0008-5472.CAN-07-5176, 18339876.
32. Decock J, Paridaens R, Cufer T. Proteases and metastasis: clinical relevance nowadays?. Curr Opin Oncol 2005, 17:545-550. 10.1097/01.cco.0000180435.39614.63, 16224231.
33. Jezierska A, Motyl T. Matrix metalloproteinase-2 involvement in breast cancer progression: a mini-review. Med Sci Monit 2009, 15:RA32-40.
34. Minn AJ, Gupta GP, Siegel PM, Bos PD, Shu W, Giri DD, Viale A, Olshen AB, Gerald WL, Massague J. Genes that mediate breast cancer metastasis to lung. Nature 2005, 436:518-524. 10.1038/nature03799, 1283098, 16049480.
35. Guzman M, Duarte MJ, Blazquez C, Ravina J, Rosa MC, Galve-Roperh I, Sanchez C, Velasco G, Gonzalez-Feria L. A pilot clinical study of Delta9-tetrahydrocannabinol in patients with recurrent glioblastoma multiforme. Br J Cancer 2006, 95:197-203. 10.1038/sj.bjc.6603236, 2360617, 16804518.
36. Natrajan R, Lambros MB, Rodriguez-Pinilla SM, Moreno-Bueno G, Tan DS, Marchio C, Vatcheva R, Rayter S, Mahler-Araujo B, Fulford LG, et al. Tiling path genomic profiling of grade 3 invasive ductal breast cancers. Clin Cancer Res 2009, 15:2711-2722. 10.1158/1078-0432.CCR-08-1878, 19318498.